Margaret Izabella Chustecki, MD, MBA

Dr. Chustecki was involved in the following clinical trials:

1. A Randomized, Double-Blind Study to Compare the Efficacy and Safety of Fixed Low Doses of Coumadin plus Aspirin to Aspirin Alone in the Prevention of Reinfarction, Cardiovascular Death and Stroke in Post Myocardial Infarction Patient
2. Evaluation of Autonomic Function by Heart Rate Variability in Patients with Mitral Valve Prolapse
3. Correlation of Platelet Activation, Platelet PADGEM Expression during Percutaneous Transluminal Angioplasty with Rate of Early Restenosis
4. Response to T-pa Therapy in Transgenic Mice with Human Apolipoprotein Measured by Nuclear Scan
5. Establishing Value as a Lescol Usage and Treatment Efficacy
6. Research on the Effects of Aceon Tablets in Hypertensive Subjects in a Community Trial
7. Cardiazem LA P.L.A.C.E. Program
8. A Long-Term Outcomes Study to Assess Statin Residual Risk Reduction with XXXXX in High Cardiovascular Risk Patients with Hypertriglyceridemia
9. A Multi-Centre, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase III Trial to Evaluate the Safety and Efficacy of Add-On Therapy with XXXXX and XXXXX added to Metformin compared to Add-On Therapy with XXXXX in combination with Metformin or XXXXX in combination with Metformin in Patients with Type 2 Diabetes who have Inadequate Glycaemic Control on Metformin Alone
10. A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of XXXXX in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
11. A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of XXXXX Compared to XXXXX, XXXXX, and XXXXX, as an Active Control, on Lung Function over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
12. An Open-Label, Long-Term Safety and Tolerability Study of XXXXX in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
13. A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of XXXXX Administered Intravenously in Patients with Migraines
14. A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi- Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the XXXXX in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) –XXXXX Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (XXXXX)
15. A Multicenter Study Conducted to Evaluate the Performance of the XXXXX Test in Laboratory and Point of Care Testing Sites
16. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF XXXXX ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT
17. A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF XXXXX COMPARED TO XXXXX ADDED TO BACKGROUND LIPID-MODIFYING THERAPY IN PATIENTS WITH ELEVATED LDL-C WHO ARE STATIN INTOLERANT
18. AN OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE III STUDY TO COMPARE THE IMMUNOGENICITY, EFFICACY, AND SAFETY OF GAN & LEE PHARMACEUTICALS XXXXX INJECTION TO XXXXX (XXXXX INJECTION) IN ADULT SUBJECTS WITH TYPE 1 DIABETES MELLITUS
19. AN OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE III STUDY TO COMPARE THE IMMUNOGENICITY, EFFICACY, AND SAFETY OF GAN & LEE PHARMACEUTICALS INSULIN XXXXX INJECTION TO XXXXX (XXXXX INJECTION) IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS
20. A Phase 2a Randomized, Double-blind, Placebo-controlled, Parallel-designed Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of XXXXX in Subjects with Stable Coronary Heart Disease
21. A Phase 2, Double-Blind, Placebo-Controlled, 3-Month Trial of XXXXX versus XXXXX in Patients with Type 2 Diabetes Mellitus
22. A Phase 2 Study of Once-Weekly XXXXX Compared with XXXXX and XXXXX in Patients with Type 2 Diabetes Mellitus
23. A Phase 2, 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of XXXXX for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis
24. A Phase 3, Multicenter, Observational Long-term Study Evaluating the Safety, Tolerability, and Efficacy of Treatment of XXXXX or XXXXX Previously Injected in the Target Knee Joint of Subjects with Moderately to Severely Symptomatic Osteoarthritis
25. XXXXX TO REDUCE CARDIOVASCULAR OUTCOMES BY REDUCING TRIGLYCERIDES IN PATIENTS WITH DIABETES (XXXXX)
26. Efficacy and Safety of Fast-acting Insulin XXXXX Compared to XXXXX both in Combination with Insulin XXXXX with or without XXXXX in Adults with Type 2 Diabetes
27. A trial comparing the efficacy and safety of insulin XXXXX and insulin XXXXX in subjects with type 2 diabetes mellitus inadequately treated with basal insulin, with or without oral antidiabetic drugs
28. Phase 4/post-marketing - A randomised, cross-over, open-label, multi-centre trial comparing the effect of XXXXX and XXXXX, with or without XXXXX in subjects with type 2 diabetes using flash glucose monitoring
29. A 26-week randomized, open-label, active-controlled, 2-treatment arm, parallel group multi-center study, comparing the efficacy and safety of XXXXX versus XXXXX in ethnically/racially diverse patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic agents Phase 3b
30. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of XXXXX on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk
31. A Randomized, Double-Blind, Parallel Group, Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of XXXXX to XXXXX and XXXXX in Subjects With Persistent Asthma
32. A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of XXXXX in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Non-hospitalized Subjects With Influenza A Infection who Are at Risk of Developing Complications
33. A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of XXXXX in the Acute Treatment of Migraine
34. A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety of XXXXX in Patients with New Onset or Established Type 1 Diabetes Mellitus (XXXXX)
35. A Phase 3 Randomized, Double-blind, Multi-dose, Placebo and NSAID-controlled Study to Evaluate the Efficacy and Safety of XXXXX in Patients with Pain Due to Osteoarthritis of the Knee or Hip
36. Efficacy and Safety of XXXXX Once Weekly versus XXXXX in Patients with Type 2 Diabetes and Increased Cardiovascular Risk (XXXXX)
37. XXXXX TO REDUCE CARDIOVASCULAR OUTCOMES BY REDUCING TRIGLYCERIDES IN PATIENTS WITH DIABETES (XXXXX)
38. A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of XXXXX versus XXXXX Once Weekly as Add-on Therapy to XXXXX in Patients with Type 2 Diabetes (XXXXX)
39. A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Study of XXXXX Administered Orally for 12 Weeks to Treat Abdominal Pain in Patients with Diarrhea-predominant Irritable Bowel Syndrome
40. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of XXXXX in Subjects with Moderate to Advanced Diabetic Kidney Disease
41. Evaluation of the XXXXX Test in an Average Patient Screening Episode (XXXXX)
42. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of XXXXX in Subjects with Diabetic Peripheral Neuropathic Pain
43. Reference Population Interval Evaluation with Access XXXXX Enrollment and Specimen Collection
44. The Effect of XXXXX versus XXXXX plus standard of care on Major Cardiovascular Events in Patients with Type 2 Diabetes
45. A Study to Support the Radiographic Eligibility Screening Process of XXXXX Studies in Symptomatic Knee Osteoarthritis Subjects
46. A Phase 3, 28-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Injection of XXXXX Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects
47. A Study of XXXXX in Participants with Type 2 Diabetes using Continuous Glucose Monitoring
48. A Double-Blinded, Placebo-controlled, Double Dummy, Multi-center Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of XXXXX in Subjects with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Two or Three Oral Glucose-lowering Agents
49. A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral XXXXX in Migraine Prevention
50. A Post Approval Study to Evaluate the Safety of the Eversense® Continuous Glucose Monitoring (CGM) System Used Non-adjunctively
51. A Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Chronic Pain
52. Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate XXXXX for the Treatment of Diabetic Peripheral Neuropathic Pain
53. Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate XXXXX for the Treatment of Osteoarthritis Pain
54. A Phase 3, Parallel-Design, Open-Label, Randomized Controlled Study to Evaluate the Efficacy and Safety of XXXXX as a Weekly Basal Insulin Compared to XXXXX in Adults with Type 2 Diabetes on Multiple Daily Injections
55. A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of XXXXX Versus XXXXX in Adult Participants with Episodic Migraine
56. A Phase 3, Open-label, Multi-center, Single-arm Study to Assess Contraceptive Efficacy and Safety of the XXXXX + XXXXX Combined Oral Contraceptive (XXXXX) in Premenopausal Females Aged 14 to 35 Years (Inclusive)
57. Evaluation of the XXXXX Test in an Average Patient Screening Episode (XXXXX)